Option chain shows key data for OncoCyte's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OncoCyte.

OncoCyte (NASDAQ:OCX) Stock, Option Chain

OncoCyte

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Pre-Market Outlook

ALLR

BPTS

MARPS

SINT

Shares of  Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals.

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Short Ideas

CRIS

RVMD

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q2

OncoCyte Corp

Morgan Stanley analyst Joseph Moore downgrades Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) from Overweight to Equal-Weight and maintains the price target from $142 to $142.

Downgrades

Price Target

Analyst Ratings

ALAB

Morgan Stanley Downgrades Astera Labs to Equal-Weight, Maintains Price Target to $142

Morgan Stanley analyst John Glass downgrades Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) from Equal-Weight to Underweight and lowers the price target from $22 to $14.

Morgan Stanley Downgrades Wendy's to Underweight, Lowers Price Target to $14

<a href="https://www.wsj.com/real-estate/commercial/the-u-s-government-has-a-landlord-and-trump-isnt-a-fan-872c469e" title="https://www.wsj.com/real-estate/commercial/the-u-s-government-has-a-landlord-and-trump-isnt-a-fan-872c469e">https://www.wsj.com/real-estate/commercial/the-u-s-government-has-a-landlord-and-trump-isnt-a-fan-872c469e</a>

iShares Trust Dow Jones US Real Estate Fund Index

The Wall Street Journal Reported The Trump Administration Is Considering Selling Two-thirds Of The Federal Government's Office Stock To The Private Sector

Morgan Stanley analyst John Glass downgrades Yum Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) from Overweight to Equal-Weight and lowers the price target from $158 to $140.

Morgan Stanley Downgrades Yum Brands to Equal-Weight, Lowers Price Target to $140

Shares of INNOVATE Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/VATE">pre-market trading</a>.
INNOVATE announced the FDA approval of MediBeacon&#8217;s TGFR System For accurate kidney function testing.
INNOVATE shares jumped 19.4% to $6.10 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>EON Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) gained 89.2% to $1.93 in pre-market trading.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) rose 62.5% to $3.04 in pre-market trading after falling 3% on Friday.</li>
<li>Crown Electrokinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) rose 43.5% to $0.1794 in pre-market trading. Crown Electrokinetics shares jumped around 57% on Friday after the company announced it entered into an exclusive partnership with Electro Scan.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) gained 30.7% to $2.33 in pre-market trading. Trio Petroleum said as of Jan. 7, it has fully repaid senior secured convertible promissory notes with aggregate principal of $1.6 million.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 22.9% to $43.21 in pre-market trading.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) gained 22.8% to $0.9185 in pre-market trading.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) gained 22.6% to $1.63 in pre-market trading.</li>
<li>First Foundation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) gained 12.7% to $7.09 in pre-market trading. First Foundation will release its fourth quarter 2024 earnings results before the opening bell on Thursday, Jan. 30.</li>
<li>Riskified Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) gained 9.2% to $5.49 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Canoo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) fell 72.3% to $0.3736 in pre-market trading after the company announced Chapter 7 bankruptcy filing, ending operations effective immediately.</li>
<li>Orangekloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) shares fell 30.3% to $0.78 in pre-market trading after dipping 72% on Friday.</li>
<li>Treace Medical Concepts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) fell 29.4% to $6.14 in pre-market trading after gaining over 5% on Friday.</li>
<li>IF Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IROQ#NASDAQ">IROQ</a>) shares dipped 29.4% to $18.00 in pre-market trading after gaining 6% on Friday.</li>
<li>TechTarget, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) shares tumbled 19.5% to $14.00 in pre-market trading.</li>
<li>Elicio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares fell 19.4% to $5.10 in pre-market trading.</li>
<li>Baird Medical Investment Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) fell 18.2% to $7.24 in today's pre-market trading after jumping 63% on Friday.</li>
<li>Rayonier Advanced Materials Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAM#NYSE">RYAM</a>) declined 17.1% to $6.24 in pre-market trading</li>
<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) fell 16.2% to $50.98 in pre-market trading after the company announced weak quarterly earnings.</li>
<li>SWK Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKH#NASDAQ">SWKH</a>) dipped 14.3% to $14.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43089042/3m-netflix-and-3-stocks-to-watch-heading-into-tuesday">3M, Netflix And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

ATPC

BDMD

CGBS

CRKN

DWTX

New Oriental Education & Technology Group

ELTX

EONR

FFWM

GOEV

IROQ

ORKT

RSKD

RYAM

SWKH

TMCI

TPET

TTGT

VATE

Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket

Amazon.com Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) autonomous driving unit Zoox is reportedly looking to begin offering rides to the public &#8220;quite soon.&#8221;
What Happened: Zoox co-founder Jesse Levinson <a href="https://www.cnbc.com/2025/01/17/amazon-zoox-plans-commercial-expansion.html">told</a> CNBC that the company intends to offer rides to the public and significantly grow its fleet of self-driving vehicles in 2025.
Zoox is currently testing its vehicles on the roads of San Francisco, Las Vegas, and Foster City, California. 
According to CNBC, the company will first launch commercial services in Las Vegas, followed by San Francisco. The company will launch an &#8220;early rider program&#8221; in Las Vegas in the coming months and open rides to the public later this year, the report said.
Zoox is also eyeing expansion to Miami and Austin, Levinson told CNBC, without detailing a timeline. 
"I don't want to imply that it'll be a commercially meaningful business this year … but it's going to be useful in terms of customers will be able to get value out of it and actually use it to go places. We're excited for that," Levinson told CNBC. "We've taken a pretty conservative and steady approach to scaling and rolling out, just because of the safety-critical nature."
Why It Matters: Zoox, once operational, will be up against Alphabet&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Waymo which is already operating its robotaxis in Phoenix and Los Angeles.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is also looking to join the robotaxi business in 2025. During the company's third-quarter earnings call last year, Elon Musk said that the company expects to start a ride-hail service in Texas and California starting next year, <a href="https://www.benzinga.com/news/24/10/41484511/palo-alto-may-open-streets-to-tesla-robotaxis-but-california-regulators-will-decide-fate" target="_blank" rel="noreferrer noopener">subject to regulatory approval</a>, with Model 3 and Model Y vehicles equipped with its full self-driving (FSD) driver assistance technology.
However, the vehicles might not all operate as driverless robotaxis but with a driver as some states demand it until the company touches certain milestones in terms of miles and hours driven, the company then said. Musk, known for overestimating his company&#8217;s products, expressed confidence about the&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne" target="_blank" rel="noreferrer noopener">company operating driverless paid rides sometime in 2025</a> despite its FSD technology not achieving fully autonomous driving yet. 
Levinson in October dismissed the possibility of Tesla deploying autonomous vehicles without safety drivers in California this year,&nbsp;<a href="https://www.benzinga.com/news/24/10/41645383/elon-musk-slams-zoox-co-founder-over-fsd-criticism-your-company-would-be-dead-already-if-not-for-ama" target="_blank" rel="noreferrer noopener">alleging that the EV giant&nbsp;</a>lacks a technology that works.
Tesla is faced with a lot of regulatory hurdles that they haven&#8217;t even started trying to climb yet, Levinson&nbsp;<a href="https://www.youtube.com/watch?v=RwFzIm-M6TU" target="_blank" rel="noreferrer noopener">said</a>&nbsp;at the TechCrunch Disrupt 2024 event in San Francisco. But the fundamental problem, he said, is that Tesla doesn&#8217;t have a &#8220;technology that worked.&#8221;
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Photo courtesy: Zoox

Tech

Media

AMZN

GOOG

GOOGL

TSLA

Amazon's Zoox Eyes Joining Leagues Of Waymo In 2025, To Offer Rides To Public 'Quite Soon'

Macro Economic Events

Econ #s

Economics

Eurozone ZEW Economic Sentiment For January 18.0 Vs. 16.9 Est.; 17.0 Prior

Germany ZEW Economic Sentiment For January 10.3 Vs. 15.2 Est.; 15.7 Prior

Morgan Stanley analyst John Glass upgrades Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) from Equal-Weight to Overweight and raises the price target from $205 to $213.

Upgrades

TXRH

Morgan Stanley Upgrades Texas Roadhouse to Overweight, Raises Price Target to $213

Germany ZEW Current Conditions For January -90.4 Vs. -93.1 Est.; -93.1 Prior

MBWM

Mercantile Bank Corporation Says Overall Financial Standing And Commercial Loan Funding Will Allow Company To Meet Challenges Arising From Changing Operating Environments

Mercantile Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBWM#NASDAQ">MBWM</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.14 by 7.02 percent. This is a 2.4 percent decrease over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $58.500 million which beat the analyst consensus estimate of $57.378 million by 1.96 percent. This is a 2.72 percent increase over sales of $56.949 million the same period last year.

Earnings

Earnings Beats

Mercantile Bank Q4 2024 GAAP EPS $1.22 Beats $1.14 Estimate, Sales $58.500M Beat $57.378M Estimate

Net interest income was Baht 149,376 million, a slight increase of Baht 932 million or 0.63% from the previous year partly due to limited loan growth in line with the economic situation and the enhancement of credit underwriting processes to ensure quality lending. Net interest margin ratio stood at 3.64%, a slight decrease from the previous year. Non-interest income was Baht 48,570 million, an increase of Baht 4,361 million or 9.86% mainly due to increased fee income from customer's wealth management service through the offering of comprehensive financial products from the Bank and its subsidiaries, as well as partners. Additionally, there was an increase in gains from financial instruments measured at fair value through profit or loss and investment income, along with increased revenue from foreign exchange transactions which were in line with the recovery of tourism.

KPCPY

Kasikornbank Public Company Q4 Net Interest Income Baht 36,345M Down 6.5% YoY; EPS Bhat 4.43 Up 11.9% YoY

Mercantile Bank Corporation Declared Regular Quarterly Cash Dividend Of $0.37 Per Common Share, Which Is  5.7% Higher Than Cash Dividends Paid During Q1 Of 2024; Dividend Is Payable On March 19, 2025

General

Know Labs Forms New Business Unit To Cater To intellectual Property Portfolio

Editor&#8217;s Note: This story has been updated to include premarket price movements.
MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares dropped 3.43% in Tuesday premarket, falling to $382.90 as cryptocurrency markets reacted to President Donald Trump&#8216;s inauguration speech that notably <a href="https://www.benzinga.com/25/01/43086698/crypto-market-plunges-after-trumps-inaugural-speech-fails-to-mention-digital-assets">omitted any mention of digital assets</a>.
What Happened: The enterprise software company, which holds over $45 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), had seen its stock surge 8.04% to $396.50 on Friday amid optimism about Trump&#8217;s anticipated crypto-friendly policies. 
The company&#8217;s executive chairman Michael Saylor attended a &#8220;Crypto Ball&#8221; last Friday where he met with Trump&#8217;s incoming cabinet members, fueling speculation about <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43078515/michael-saylor-meets-trumps-cabinet-at-crypto-ball-what-does-the-bitcoin-bulls-cryptic-post-indicate">favorable cryptocurrency regulations</a>.
However, Trump&#8217;s inaugural address focused instead on traditional assets, declaring the start of a &#8220;Golden Age of America&#8221; &#8211; a reference that prompted Bitcoin critic Peter Schiff to highlight the president&#8217;s apparent preference for gold over cryptocurrency. 
See Also: <a href="https://www.benzinga.com/25/01/43088034/bitcoin-ethereum-dogecoin-retrace-from-pre-inauguration-highs-as-trumps-address-disappoints-analyst-highlights-possibility-of-btc-consolidation-in-101k-106k-range">Bitcoin, Ethereum, Dogecoin Retrace From Pre-Inauguration Highs As Trump Skips Crypto Mention: Analyst Highlights BTC Consolidation In $101K-$106K Range</a>
Why It Matters: The speech&#8217;s omission of digital assets triggered a broader <a href="https://www.benzinga.com/25/01/43088563/bitcoin-vs-gold-peter-schiff-decodes-trumps-golden-age-reference-in-inaugural-speech">crypto market decline</a>, with Bitcoin falling from $106,000 to $101,775.
The selloff comes as Trump named Mark Uyeda as acting U.S. Securities and Exchange Commission chair, replacing Gary Gensler. 
The firm has been purchasing Bitcoin for ten consecutive weeks, according to its public disclosures.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43088840/donald-and-melania-trump-memecoins-crash-after-presidential-inaugurationfirst-couples-crypto-wealth-plunges-36">Donald And Melania Trump Memecoins Crash, Erode Billions In Investors&#8217; Wealth</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

$BTC

MSTR

MicroStrategy Drops Nearly 4% In Tuesday Premarket After Trump's Inauguration Speech Sidelines Cryptocurrency, Bitcoin Retreats Below $102K (UPDATED)

Keefe, Bruyette &amp; Woods analyst Wood Lay initiates coverage on Firstsun Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) with a Outperform rating and announces Price Target of $46.

Initiation

FSUN

Keefe, Bruyette & Woods Initiates Coverage On Firstsun Capital with Outperform Rating, Announces Price Target of $46

Highlights and Key Items:
<ul>
<li>Recorded full year 2024 sales volumes of 24,100 to 24,600 working interest ("WI") barrels of oil equivalent per day ("BOEPD"), at the midpoint of its guidance range of 23,500 to 25,100 WI BOEPD;
<ul>
<li>Full year 2024 sales volumes were 19,400 to 19,800 net revenue interest ("NRI") BOEPD, at the midpoint of the Company's guidance range of 18,800 to 20,300 NRI BOEPD;</li>
</ul>
</li>
<li>Generated Q4 2024 sales volumes of about 23,600 to 24,000 WI BOEPD, or 19,100 to 19,500 NRI BOEPD, both within guidance;</li>
<li>Produced between 24,550 and 25,050 WI BOEPD for full year 2024, in line with the midpoint of its full year guidance range of 24,100 to 25,400 WI BOEPD;
<ul>
<li>Full year 2024 production volumes were 19,800 to 20,200 NRI BOEPD, above the midpoint of the Company's guidance range of 19,300 to 20,600 NRI BOEPD; and</li>
</ul>
</li>
<li>Delivered Q4 2024 production of about 25,100 to 25,600 WI BOEPD, or 20,600 to 21,000 NRI BOEPD, in line with guidance.</li>
</ul>

VAALCO Energy Reports Record 2024 Sales Volumes Of 24,100-24,600 BOEPD, Exceeding Guidance Midpoints

New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) reported quarterly adjusted earnings of $0.22 per share which missed the analyst consensus estimate of $0.30 by 26.67 percent. This is a 24.14 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $1.04 billion which beat the analyst consensus estimate of $1.03 billion by 0.78 percent. This is a 19.37 percent increase over sales of $869.60 million the same period last year.

Earnings Misses

New Oriental Education Q2 Adj $0.22 Misses $0.30 Estimate, Sales $1.04B Beat $1.03B Estimate

The company will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST

IRON

Reported Monday, Disc Medicine Announces Conference Call To Review FDA Feedback On Bitopertin For EPP

OncoCyte GAAP EPS of -$0.98 misses by $0.54, revenue of $0.11M misses by $0.06M

Oncocyte's (OCX) cash, cash equivalents, and restricted cash balance at the end of the third quarter was approximately $5.1M down $5.9M sequentiall...

OncoCyte reports Q3 EPS (98c), consensus (44c)

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

OncoCyte Corp ( ($OCX) ) has released its Q3 earnings. Here is a breakdown of the information OncoCyte Corp presented to its investors. OncoCyte Co...

OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates

Michael Matson, an analyst from Needham, maintained the Buy rating on OncoCyte (OCX – Research Report). The associated price target remains the sam...

OncoCyte's Strategic Advances and Financial Prudence Justify Buy Rating

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Akoya Biosciences (AKYA – Research Report), OncoCyte (OCX – Resea...

Analysts Offer Insights on Healthcare Companies: Akoya Biosciences (AKYA), OncoCyte (OCX) and Healthequity (HQY)

Oncocyte (OCX) announced additional data regarding its lead assay VitaGraft, which was published in the journal, Nephrology Dialysis Transplantatio...

OncoCyte announces VitaGraft data published in journal

Oncocyte (OCX) announced the publication of data regarding its DetermaCNI assay. In a paper recently published in the journal Acta Neuropathologica...

OncoCyte announces publication of DetermaCNI assay data

Oncocyte (OCX) announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. In this part-time role, he will su...

OncoCyte appoints Billings as consulting CMO

Oncocyte names Paul Billings as consulting chief medical officer

AKYA

Health Care

Press Releases

Oncocyte Signs Leading Transplant Centers in US and Germany

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Biotech

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms

Comments

OncoCyte

OncoCyte (OCX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga